banner

Posts tagged as: CXM news back to homepage

Cardium Wins Patent Rights to Heart Disease Treatment, Settles Dispute with Boston Scientific Cardium Wins Patent Rights to Heart Disease Treatment, Settles Dispute with Boston Scientific(0)

Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease

Resolves Long-standing Competition with Boston Scientific Corporation Over Rights to Cardiovascular Gene Therapy in the U.S. and Europe

Cardium Therapeutics (NYSE MKT: CXM) today announced a winning patent decision in Europe and successful resolution of a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific Corporation (NYSE: BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy Read More

Cardium Therapeutics Excellagen Launch Timely with Rising Trend in Diabetic Foot Ulcers Cardium Therapeutics Excellagen Launch Timely with Rising Trend in Diabetic Foot Ulcers(0)

Demographic trends towards an aging population, soaring diagnosis rates in diabetes, obesity and cardiovascular disease are just a few of the factors that are driving growth and spurring innovation to better serve millions of wound care patients each year.  The wound care industry has many verticals for sales, but probably none more critical than diabetic foot ulcers.  Diabetic foot ulcers affect about 15 percent of the nearly 26 million people with diabetes in the United States, and Read More

Cardium Therapeutics Aligned in Neutraceutical Market Set to Reach $243 Billion by 2015 Cardium Therapeutics Aligned in Neutraceutical Market Set to Reach $243 Billion by 2015(0)

Late in September, a comprehensive report by Global Industry Analysts, Inc. stated that the global nutraceutical market will cross $243 Billion by 2015, “owing to consumer desire for leading a healthy life and increasing scientific evidence supporting health foods.”

The research firm also attributes the strong growth rate to an aging population and rising healthcare costs as catalysts for the neutraceutical industry that it calls “one of the brightest spots in a global market suffering from its worst economic Read More

Excellagen Presentation on Cardium Therapeutics Website Excellagen Presentation on Cardium Therapeutics Website(0)

An updated presentation for Excellagen has been published on the Cardium Therapeutics (NYSE MKT: CXM) website.  The pdf file is available for viewing/dowloading at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations. Read More

Cardium Forms Excellagen Medical Advisory Board for Wound Care Product Cardium Forms Excellagen Medical Advisory Board for Wound Care Product(0)

Cardium Therapeutics Ltd. (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and business with the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR), said today that they have assembled a new Excellagen Medical Advisory Board as part of corporate initiatives Read More

Cardium to Present at Rodman and Renshaw Conference Cardium to Present at Rodman and Renshaw Conference(0)

Cardium to Present at the Rodman & Renshaw Annual 2012 Healthcare Investment Conference

Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012 at 3:15 p.m. Eastern Time. The conference is being held September 9-11, 2012 at the Waldorf-Astoria Hotel in New York City. An audio webcast of the Company’s presentation will be available live and by replay and can be accessed at Read More

Cardium and Generx Featured on San Diego Biotechnology Connection Cardium and Generx Featured on San Diego Biotechnology Connection(0)

An article this morning on San Diego Biotechnology Connection website, discusses an important breakthrough in technology and regenerative medicine.  The article provides details of Cardium Therapeutics (NYSE MKT: CXM) and its Generx product candidate, a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease.  The article titled, “Cardium Therapeutics reports advance – gene therapy process technology” was written by Rex Graham, a science journalist with a master’s degree in microbiology and a 30-year career Read More

Cardium Therapeutics Releases Excellagen Case Studies Cardium Therapeutics Releases Excellagen Case Studies(0)

Cardium Therapeutics (NYSE MKT: CXM) has released new case study information on its Excellagen wound care management product. Excellagen is a new, highly-refined bovine Type I collagen–based topical gel designed to support favorable wound care management. Excellagen’s unique high molecular weight sterile, collagen formulation is topically applied through easy to control, pre-filled, single-use syringes. It is recommended that Excellagen be applied Read More

Cardium Therapeutics Excellagen Named as Top Ten Innovation in Podiatry Cardium Therapeutics Excellagen Named as Top Ten Innovation in Podiatry(0)

Last year, industry specialist GlobalData released a report estimating the global diabetic foot ulcer therapeutics market to be valued at $1.15 billion in 2010 with expectations of growth to $2.28 billion by 2017.  A recent article by BBC News called today’s diabetic foot care “appalling” and leading to “an increased risk of having a foot amputated.”  With their Excellagen product, Cardium Therapeutics (NYSE MKT: CXM), a company in the same industry as Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR), Read More

Cardium Therapeutics in the News Cardium Therapeutics in the News(0)

It’s been a busy several weeks for Cardium Therapeutics (NYSE MKT: CXM) as industry attention and investor buzz continues to build around regenerative medicine companies. Generx®, Cardium’s flagship gene therapy product candidate, is a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. In March 2012, Cardium initiated its Phase 3 registration clinical trial in Russia which is expected to enroll approximately 100 patients at up to eight leading cardiovascular centers. The San Diego Biotechnology Read More



Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.